Search in:

Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 1

Submit an article Journal homepage

281

Views

CrossRef citations to date

Altmetric

Review

Treatment strategies for pediatric acute myeloid leukemia

Michael J Absalon University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Division of Hematology/Oncology, Cincinnati, OH, USA +1 513 636 4266; +1 513 636 3549; [email protected]

, MD PhD &

Franklin O Smith University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Division of Hematology/Oncology, Cincinnati, OH, USA +1 513 636 4266; +1 513 636 3549; [email protected]

, MD

Pages 57-79 | Published online: 16 Dec 2008

Cite this article
https://doi.org/10.1517/14656560802627929

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Weissman IL. The E Donnall Thomas lecture: normal and neoplastic stem cells. Biol Blood Marrow Transplant 2008;14:849-58
PubMedGoogle Scholar
Warner JK, Wang JC, Hope KJ, et al. Concepts of human leukemic development. Oncogene 2004;23:7164-77
PubMed Web of Science ®Google Scholar
Xie Y, Davies SM, Xiang Y, et al. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003;97:2229-35
PubMed Web of Science ®Google Scholar
Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006;107:2099-107
PubMed Web of Science ®Google Scholar
Owen C, Barnett M, Fitzgibbon J. |Familial myelodysplasia and acute myeloid leukaemia–a review. Br J Haematol 2008;140:123-32
PubMed Web of Science ®Google Scholar
Viniou N, Terpos E, Rombos J, et al. Acute myeloid leukemia in a patient with ataxia-telangiectasia: a case report and review of the literature. Leukemia 2001;15:1668-70
PubMed Web of Science ®Google Scholar
Frohling S, Scholl C, Gilliland DG, et al. Genetics of Myeloid Malignancies: pathogenetic and clinical implications. J Clin Oncol 2005;23:6285-95
PubMed Web of Science ®Google Scholar
Scholl C, Gilliland DG, Fröhling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 2008;35:336-45
PubMed Web of Science ®Google Scholar
Steffen B, Müller-Tidow C, Schwäble J, et al. The molecular pathogenesis of acute myeloid leukemia. Crit Rev Oncol Hematol 2005;56:195-221
PubMed Web of Science ®Google Scholar
Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007;92:1519-32
PubMed Web of Science ®Google Scholar
Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 2005;19:2025-9
PubMed Web of Science ®Google Scholar
Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505-15
PubMed Web of Science ®Google Scholar
Forestier E, Izraeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood 2008;111:1575-83
PubMed Web of Science ®Google Scholar
Zwaan MC, Reinhardt D, Hitzler J, et al. Acute leukemias in children with down syndrome. Pediatr clin North Am 2008;55:53-70
PubMed Web of Science ®Google Scholar
Hande KR, Stein RS, McDonough DA, et al. Effects of high-dose cytarabine. Clin Pharmacol Ther 1982;31:669-74
PubMed Web of Science ®Google Scholar
Kufe DW, Major PP, Egan EM, et al. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 1980;255:8997-8900
PubMed Web of Science ®Google Scholar
Fram RJ, Kufe DW. DNA strand breaks caused by inhibitors of DNA synthesis: 1-beta-D-arabinofuranosylcytosine and aphidicolin. Cancer Res 1982;42:4050-3
PubMed Web of Science ®Google Scholar
Daly PF, Zugmaier G, Sandler D, et al. Regulation of the cytidine phospholipid pathways in human cancer cells and effects of 1-beta-D-arabinofuranosylcytosine: a noninvasive 31P nuclear magnetic resonance study. Cancer Res 1990;50:552-7
PubMedGoogle Scholar
Koehler KA, Hines J, Mansour EG, et al. Comparison of the membrane-related effects of cytarabine and other agents on model membranes. Biochem Pharmacol 1985;34:4025-31
PubMed Web of Science ®Google Scholar
Kucera GL, Capizzi RL. 1-beta-D-arabinofuranosylcytosine-diphosphate-choline is formed by the reversal of cholinephosphotransferase and not via cytidylyltransferase. Cancer Res 1992;52:3886-91
PubMedGoogle Scholar
Momparler RL, Fischer GA. Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J Biol Chem 1968;243:4298-304
PubMed Web of Science ®Google Scholar
Amici A, Emanuelli M, Magni G, et al. Pyrimidine nucleotidases from human erythrocyte possess phosphotransferase activities specific for pyrimidine nucleotides. FEBS Lett 1997;419:263-7
PubMed Web of Science ®Google Scholar
Mancini WR, Cheng YC. Human deoxycytidylate deaminase. Substrate and regulator specificities and their chemotherapeutic implications. Mol Pharmacol 1983;23:159-64
PubMedGoogle Scholar
Grant S. Ara-C: cellular and molecular pharmacology. Adv Cancer Res 1998;72:197-233
PubMed Web of Science ®Google Scholar
Braess J, Voss S, Jahns-Streubel G, et al. The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity. Br J Haematol 2000;110:170-9
PubMedGoogle Scholar
Markasz L, Hajas G, Kiss A, et al. Granulocyte colony stimulating factor increases drug resistance of leukaemic blast cells to Daunorubicin. Pathol Oncol Res 2008;14:285-92
PubMedGoogle Scholar
Thomas X, Raffoux E, Botton S, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007;21:453-61
PubMed Web of Science ®Google Scholar
Hiddemann W, Kern W, Heinecke A, et al. Priming with G-CSF in acute myeloid leukemia: preliminary data of the AMLCG. Ann Hematol 2004;83(Suppl 1):S53-4
Google Scholar
Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-85
PubMed Web of Science ®Google Scholar
Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743-52
PubMed Web of Science ®Google Scholar
Hansen PB, Johnsen HE, Jensen L, et al. Priming and treatment with molgramostim (rhGM-CSF) in adult high-risk acute myeloid leukemia during induction chemotherapy: a prospective, randomized pilot study. Eur J Haematol 1995;54:296-303
PubMedGoogle Scholar
Broxmeyer H. The cell cycle as therapeutic target. Cancer Invest 1995;13:617-24
PubMed Web of Science ®Google Scholar
Rustum YM, Preisler HD. Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy. Cancer Res 1979;39:42-9
PubMed Web of Science ®Google Scholar
Plunkett W, Iacoboni S, Estey E, et al. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 1985;12:20-30
PubMed Web of Science ®Google Scholar
Estey E, Plunkett W, Dixon D, et al. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987;1:580-3
PubMed Web of Science ®Google Scholar
Kantarjian HM, Estey EH, Plunkett W, et al. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 1986;81:387-94
PubMed Web of Science ®Google Scholar
Raza A, Gezer S, Anderson J, et al. Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study. Exp Hematol 1992;20:1194-200
PubMedGoogle Scholar
Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 2006;107:116-24
PubMed Web of Science ®Google Scholar
Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903
PubMed Web of Science ®Google Scholar
Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841-51
PubMed Web of Science ®Google Scholar
Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710-7
PubMed Web of Science ®Google Scholar
Becton D, Dahl GV, Ravindranath Y, et al. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood 2006;107:1315-24
PubMed Web of Science ®Google Scholar
Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173-9
PubMed Web of Science ®Google Scholar
Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999;17:3767-75
PubMed Web of Science ®Google Scholar
Zwaan CM, Kaspers GJ, Pieters R, et al. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 2002;100:3352-60
PubMed Web of Science ®Google Scholar
Mrozek K, Heinonen K, Lawrence D, et al. Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood 1997;90:4532-8
PubMed Web of Science ®Google Scholar
Kalwinsky DK, Raimondi SC, Schell MJ, et al. Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol 1990;8:75-83
PubMed Web of Science ®Google Scholar
Neubauer A, Maharry K, Mrozek K, et al. Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study. J Clin Oncol 2008;26:4603-9
PubMed Web of Science ®Google Scholar
Goemans BF, Zwaan CM, Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005;19:1536-42
PubMed Web of Science ®Google Scholar
Meshinchi S, Stirewalt DL, Alonzo TA, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 2003;102:1474-9
PubMed Web of Science ®Google Scholar
Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993;11:116-24
PubMed Web of Science ®Google Scholar
Avramis VI, Wiersma S, Krailo MD, et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a Phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin Cancer Res 1998;4:45-52
PubMed Web of Science ®Google Scholar
Estey E, Plunkett W, Gandhi V, et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 1993;9:343-50
PubMed Web of Science ®Google Scholar
Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994;12:671-8
PubMed Web of Science ®Google Scholar
Dinndorf PA, Avramis VI, Wiersma S, et al. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. J Clin Oncol 1997;15:2780-5
PubMed Web of Science ®Google Scholar
Fleischhack G, Hasan C, Graf N, et al. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a Phase II trial. Br J Haematol 1998;102:647-55
PubMed Web of Science ®Google Scholar
Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood 2008;111:1044-53
PubMed Web of Science ®Google Scholar
Milligan DW, Wheatley K, Littlewood T, et al. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 2006;107:4614-22
PubMed Web of Science ®Google Scholar
Kornblau SM, Gandhi V, Andreeff HM, et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/-cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 1996;10:1563-9
PubMed Web of Science ®Google Scholar
Gandhi V, Estey E, Keating MJ, et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 1996;87:256-64
PubMed Web of Science ®Google Scholar
Santana VM, Mirro J Jr, Kearns C, et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992;10:364-70
PubMed Web of Science ®Google Scholar
Santana VM, Hurwitz CA, Blakley RL, et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994;84:1237-42
PubMed Web of Science ®Google Scholar
Ribeiro RC, Razzouk BI, Pounds S, et al. Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000. Leukemia 2005;19:2125-9
PubMedGoogle Scholar
Razzouk BI, Raimondi SC, Srivastava DK, et al. Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. Leukemia 2001;15:1326-30
PubMedGoogle Scholar
Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 2002;3:415-24
PubMed Web of Science ®Google Scholar
Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005;19:2130-8
PubMed Web of Science ®Google Scholar
Lie SO, Abrahamsson J, Clausen N, et al. Long-term results in children with AML: NOPHO-AML Study Group–report of three consecutive trials. Leukemia 2005;19:2090-100
PubMed Web of Science ®Google Scholar
Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005;19:2101-16
PubMed Web of Science ®Google Scholar
Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003;102:4277-83
PubMed Web of Science ®Google Scholar
Smith FO, Alonzo TA, Gerbing RB, et al. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005;19:2054-62
PubMed Web of Science ®Google Scholar
Finnish-Leukaemia-Group. The effect of thioguanine on a combination of daunorubicine, cytarabine and prednisone in the treatment of acute leukaemia in adults. The Finnish Leukaemia Group. Scand J Haematol 1979;23:124-8
PubMedGoogle Scholar
Wells RJ, Woods WG, Buckley JD, et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study. J Clin Oncol 1994;12:2367-77
PubMedGoogle Scholar
Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006;24:4499-506
PubMed Web of Science ®Google Scholar
Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005;19:2030-42
PubMed Web of Science ®Google Scholar
Oki Y, Issa JP. Review: recent clinical trials in epigenetic therapy. Rev Recent Clin Trials 2006;1:169-82
PubMedGoogle Scholar
Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105:940-7
PubMed Web of Science ®Google Scholar
Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229
PubMed Web of Science ®Google Scholar
Buckley JD, Lampkin BC, Nesbit ME, et al. Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group. Med Pediatr Oncol 1989;17:382-90
PubMedGoogle Scholar
Speth PA, van de Loo FA, Linssen PC, et al. Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. Clin Pharmacol Ther 1986;40:643-9
PubMed Web of Science ®Google Scholar
Berman E, Wittes RE, Leyland-Jones B, et al. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 1983;43:6096-101
PubMed Web of Science ®Google Scholar
Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77:1666-74
PubMed Web of Science ®Google Scholar
Vogler WR, Velez-Garcia E, Weiner RS, et al. A Phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992;10:1103-11
PubMed Web of Science ®Google Scholar
Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79:313-9
PubMed Web of Science ®Google Scholar
O'Brien TA, Russell SJ, Vowels MR, et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group. Blood 2002;100:2708-16
PubMedGoogle Scholar
Faulds D, Balfour JA, Chrisp P, et al. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991;41:400-49
PubMed Web of Science ®Google Scholar
Weiss RB, Grillo-Lopez AJ, Marsoni S, et al. Amsacrine-associated cardiotoxicity: an analysis of 82 cases. J Clin Oncol 1986;4:918-28
PubMed Web of Science ®Google Scholar
Steinherz LJ, Steinherz PG, Mangiacasale D, et al. Cardiac abnormalities after AMSA administration. Cancer Treat Rep 1982;66:483-8
PubMedGoogle Scholar
Arlin ZA, Feldman EJ, Mittelman A, et al. Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Cancer 1991;68:1198-200
PubMed Web of Science ®Google Scholar
Steuber CP, Krischer J, Holbrook T, et al. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized Phase II study. J Clin Oncol 1996;14:1521-5
PubMed Web of Science ®Google Scholar
Krischer J, Land VJ, Civin CI, et al. Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study. Cancer 1984;54:207-10
PubMedGoogle Scholar
Perel Y, Auvrignon A, Leblanc T, et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit–multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. Leukemia 2005;19:2082-9
PubMed Web of Science ®Google Scholar
Kessler T, Mohr M, Muller-Tidow C, et al. Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis. Leuk Res 2008;32:491-4
PubMed Web of Science ®Google Scholar
Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood 1990;75:1932-40
PubMed Web of Science ®Google Scholar
Entz-Werle N, Suciu S, van der Werff ten Bosch J, et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia 2005;19:2072-81
PubMed Web of Science ®Google Scholar
Dedon PC, Salzberg AA, Xu J. Exclusive production of bistranded DNA damage by calicheamicin. Biochemistry 1993;32:3617-22
PubMed Web of Science ®Google Scholar
Maiese WM, Lechevalier MP, Lechevalier HA, et al. Calicheamicins, a novel family of antitumor antibiotics: taxonomy, fermentation and biological properties. J Antibiot (Tokyo) 1989;42:558-63
PubMed Web of Science ®Google Scholar
Zein N, Sinha AM, McGahren WJ, et al. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988;240:1198-201
PubMed Web of Science ®Google Scholar
van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001;97:3197-204
PubMed Web of Science ®Google Scholar
Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442-52
PubMed Web of Science ®Google Scholar
McKoy JM, Angelotta C, Bennett CL, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007;31:599-604
PubMed Web of Science ®Google Scholar
Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005;106:1183-8
PubMed Web of Science ®Google Scholar
Aplenc R, Alonzo TA, Gerbing RB, et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol 2008;26:2390-95
PubMed Web of Science ®Google Scholar
Capizzi RL, Poole M, Cooper MR, et al. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. Blood 1984;63:694-700
PubMed Web of Science ®Google Scholar
Hasle H, Abrahamsson J, Clausen N, et al. Gemtuzumab Ozagamicin Is Well Tolerated as Post-Consolidation Therapy in Childhood AML (ASH Meeting Abstracts). Blood 2007;110:a4367
PubMedGoogle Scholar
Rubnitz J, Razzouk B, Bowman P, et al. Improved Remission Induction Rate of Childhood AML: Preliminary Results of the AML02 Trial (ASH Meeting Abstracts). Blood 2005;106:a275
Google Scholar
Rots MG, Pieters R, Jansen G, et al. A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia. Eur J Cancer 2001;37:492-8
PubMed Web of Science ®Google Scholar
Zwaan CM, Kaspers GJ, Pieters R, et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 2000;96:2879-86
PubMed Web of Science ®Google Scholar
Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-9
PubMed Web of Science ®Google Scholar
Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968;32:507-23
PubMed Web of Science ®Google Scholar
Gee TS, Yu KP, Clarkson BD. Treatment of adult acute leukemia with arabinosylcytosine and thioguanine. Cancer 1969;23:1019-32
PubMed Web of Science ®Google Scholar
Chard RL Jr, Finklestein JZ, Sonley MJ, et al. Increased survival in childhood acute nonlymphocytic leukemia after treatment with prednisone, cytosine arabinoside, 6-thioguanine, cyclophosphamide, and oncovin (PATCO) combination chemotherapy. Med Pediatr Oncol 1978;4:263-73
PubMedGoogle Scholar
Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981;58:1203-12
PubMed Web of Science ®Google Scholar
Weinstein HJ, Mayer RJ, Rosenthal DS, et al. Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 1980;303:473-8
PubMed Web of Science ®Google Scholar
Weinstein HJ, Mayer RJ, Rosenthal DS, et al. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 1983;62:315-9
PubMed Web of Science ®Google Scholar
Ravindranath Y, Steuber CP, Krischer J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. J Clin Oncol 1991;9:572-80
PubMed Web of Science ®Google Scholar
Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996;87:4979-89
PubMed Web of Science ®Google Scholar
Rees JK, Gray RG. Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study. Haematol Blood Transfus 1990;33:243-8
PubMedGoogle Scholar
Pession A, Rondelli R, Basso G, et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia 2005;19:2043-53
PubMed Web of Science ®Google Scholar
Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996;334:1428-34
PubMed Web of Science ®Google Scholar
Alonzo TA, Wells RJ, Woods WG, et al. Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era. Leukemia 2005;19:965-70
PubMed Web of Science ®Google Scholar
Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56-62
PubMed Web of Science ®Google Scholar
Stevens RF, Hann IM, Wheatley K, et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998;101:130-40
PubMed Web of Science ®Google Scholar
Oliansky DM, Rizzo JD, Aplan PD, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2007;13:1-25
PubMedGoogle Scholar
Aladjidi N, Auvrignon A, Leblanc T, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003;21:4377-85
PubMed Web of Science ®Google Scholar
Pui CH, Dahl GV, Kalwinsky DK, et al. Central nervous system leukemia in children with acute nonlymphoblastic leukemia. Blood 1985;66:1062-7
PubMed Web of Science ®Google Scholar
Abbott BL, Rubnitz JE, Tong X, et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience. Leukemia 2003;17:2090-6
PubMed Web of Science ®Google Scholar
Johnston DL, Alonzo TA, Gerbing RB, et al. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol 2005;23:9172-8
PubMed Web of Science ®Google Scholar
Creutzig U, Ritter J, Zimmermann M, et al. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. J Clin Oncol 1993;11:279-86
PubMed Web of Science ®Google Scholar
Creutzig U, Reinhardt D, Diekamp S, et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005;19:1355-60
PubMed Web of Science ®Google Scholar
Baehner RL, Bernstein ID, Sather H, et al. Improved remission induction rate with D-ZAPO but unimproved remission duration with addition of immunotherapy to chemotherapy in previously untreated children with ANLL. Med Pediatr Oncol 1979;7:127-39
PubMedGoogle Scholar
Buckley JD, Chard RL, Baehner RL, et al. Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group. Cancer 1989;63:1457-65
PubMed Web of Science ®Google Scholar
Steuber CP, Civin C, Krischer J, et al. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study. J Clin Oncol 1991;9:247-58
PubMed Web of Science ®Google Scholar
Rees JK, Gray RG, Wheatley K. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party. Br J Haematol 1996;94:89-98
PubMed Web of Science ®Google Scholar
Perel Y, Auvrignon A, Leblanc T, et al. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucamie Aique Myeloide Enfant. J Clin Oncol 2002;20:2774-82
PubMed Web of Science ®Google Scholar
Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-33
PubMed Web of Science ®Google Scholar
Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 1999;94:3707-16
PubMed Web of Science ®Google Scholar
Hasle H, Alonzo TA, Auvrignon A, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood 2007;109:4641-7
PubMed Web of Science ®Google Scholar
Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999;107:69-79
PubMed Web of Science ®Google Scholar
Sievers EL, Lange BJ, Alonzo TA, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003;101:3398-406
PubMed Web of Science ®Google Scholar
Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003;123:243-52
PubMed Web of Science ®Google Scholar
Langebrake C, Creutzig U, Dworzak M, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol 2006;24:3686-92
PubMed Web of Science ®Google Scholar
Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001;61:7233-9
PubMed Web of Science ®Google Scholar
Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-18
PubMed Web of Science ®Google Scholar
Caligiuri MA, Strout MP, Lawrence D, et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 1998;58:55-9
PubMed Web of Science ®Google Scholar
Dohner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002;20:3254-61
PubMed Web of Science ®Google Scholar
Paschka P, Marcucci G, Ruppert AS, et al. Wilms Tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2008;26:4595-602
PubMed Web of Science ®Google Scholar
Langer C, Radmacher MD, Ruppert AS, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008;11:5371-9
Google Scholar
Marcucci G, Maharry K, Whitman SP, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2007;25:3337-43
PubMed Web of Science ®Google Scholar
Lugthart S, van Drunen E, van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008;111:4329-37
PubMed Web of Science ®Google Scholar
Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106:3740-6
PubMed Web of Science ®Google Scholar
Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005;23:9234-42
PubMed Web of Science ®Google Scholar
Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005;106:3747-54
PubMed Web of Science ®Google Scholar
Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004;22:624-33
PubMed Web of Science ®Google Scholar
Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006;108:3654-61
PubMed Web of Science ®Google Scholar
Zwaan CM, Meshinchi S, Radich JP, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 2003;102:2387-94
PubMed Web of Science ®Google Scholar
Brown P, McIntyre E, Rau R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007;110:979-85
PubMed Web of Science ®Google Scholar
Cazzaniga G, Dell'Oro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005;106:1419-22
PubMed Web of Science ®Google Scholar
Brown P, Small D. FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. Eur J Cancer 2004;40:707-21;discussion 22-4
PubMed Web of Science ®Google Scholar
Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108:3262-70
PubMed Web of Science ®Google Scholar
Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008;100:184-98
PubMed Web of Science ®Google Scholar
Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005;23:3971-93
PubMed Web of Science ®Google Scholar
Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59
PubMed Web of Science ®Google Scholar
Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999;94:417-28
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Treatment strategies for pediatric acute myeloid leukemia

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Treatment strategies for pediatric acute myeloid leukemia

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date